Replimune Group (REPL) Nosedives 39% as FDA Approval ... - Finviz
Stock screener for investors and traders, financial visualizations.
finviz.comHere’s the latest publicly reported news on Replimune Group (REPL) up to now.
-
FDA update on RP1: In April 2026, Replimune disclosed that the FDA issued a Complete Response Letter (CRL) for the RP1 plus nivolumab BLA in advanced melanoma, prompting the company to reassess pathways including potential accelerated approval and cost/manufacturing implications. This marked a significant setback for near-term US commercialization [StockTitan, Apr 26, 2026; Finviz, Sept 18, 2025; Investing.com coverage of the CRL reactions] [sources cited inline].
-
Corporate and financing signals: The company reported Q2 2026 financial results with ongoing efforts around a resubmission timeline and potential financing options tied to future approvals, including discussions of post-approval funding arrangements and extended debt terms. This information indicates continued emphasis on progression of RP1 and related programs despite regulatory hurdles [StockTitan, Apr 26, 2026] [sources cited inline].
-
Market reaction in 2025–2026: Following regulatory challenges and communications with the FDA, Replimune’s stock experienced substantial declines in late 2025 and early 2026 as investors weighed the likelihood of RP1 achieving approval and commercial viability. Market coverage highlighted the high unmet need in advanced melanoma and the company’s need to adapt strategy in light of regulatory feedback [Finviz, Sept 18, 2025; Yahoo Finance/Investing coverage, Apr 13, 2026] [sources cited inline].
Notes and context:
- RP1 is Replimune’s oncolytic virus therapy intended for combination with nivolumab in melanoma; the regulatory path appears uncertain, with accelerated approval remaining a potential but not guaranteed option depending on FDA feedback [StockTitan summary and CNBC-style market coverage] [sources cited inline].
- Other programs (e.g., RP2 for metastatic uveal melanoma) continue to be part of the pipeline, but the main near-term near-term focus is RP1’s regulatory status and any pending data readouts or independent reviews that could influence approval discussions [StockTitan and FINVIZ summaries] [sources cited inline].
If you’d like, I can:
- pull more precise dates and excerpts from the primary filings and press releases.
- summarize investor sentiment and price movements around key dates with a simple chart.
- track any new regulatory updates or trial readouts as they’re released.